Dr. Garon on Immunotherapy as Salvage Treatment for Advanced Lung Cancer

Name: Dr. Garon on Immunotherapy as Salvage Treatment for Advanced Lung Cancer
Uploaded: 2017-11-11T02:15:00.000Z
Description: Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses the possibility of administering PD1 or PD-L1 blockades as a third-line or salvage therapy for patients with advanced lung cancer.

November 10, 2017

Edward B. Garon, MD

Video

Conference|PER® Chemotherapy Foundation Symposium (CFS)

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses the possibility of administering PD1 or PD-L1 blockades as a third-line or salvage therapy for patients with advanced lung cancer.

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses the possibility of administering PD-1 or PD-L1 blockades as a third-line or salvage therapy for patients with advanced lung cancer.

While it is understood that these agents may work in the second-line setting for some patients, to date, researchers and clinicians are still unsure whether some patients would have more of a benefit holding a select treatment off until a later setting.

However, Garon mentioned that by examining data from recent clinical trials, researchers might be able to determine appropriate patients to receive PD-1/PD-L1 inhibitors as salvage therapy.